Trevi Therapeutics, Inc. (TRVI) NASDAQ
13.50
-0.45(-3.23%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Trevi Therapeutics, Inc.
Address
195 Church Street
New Haven, CT 06510
United States of America (the)
Phone
203 304 2499
Sector
Healthcare
Industry
Biotechnology
Employees
31
First IPO Date
May 07, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Jennifer L. Good | Co-Founder, Chief Executive Officer, President & Director | 976,632 | 1965 |
| Farrell Simon | Chief Commercial Officer | 530,567 | N/A |
| Thomas R. Sciascia | Co-Founder & Chief Scientific Officer | 551,426 | 1953 |
| James V. Cassella | Chief Development Officer | 694,770 | 1955 |
| Christopher Galletta | Controller & Chief Accounting Officer | 0 | 1978 |
| Katherine Takaki | Senior Vice President of Global Regulatory Affairs | 0 | N/A |
| Katie McManus | Communications Manager | 0 | N/A |
| David C. Hastings | Chief Financial Officer & Principal Financial Officer | 0 | 1961 |
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
